Immunotherapies have been approved in the United States and elsewhere to treat a variety of cancers and are prescribed to patients by oncologists. These approvals are the result of years of research and testing designed to demonstrate the effectiveness of these treatments. Immunotherapies are also available through clinical trials, which are carefully controlled and monitored studies involving patient volunteers. BioCytoceutials is the established leading expert in TCR and CAR T&NK cell immune therapy development, as we offer the one-stop custom services that cover the entire new drug development pipeline.
A major advantage of using mAbs rather than PoAbs is the potential availability of almost infinite quantities of a specific mAb directed toward a single epitope. Therefore mAbs have been used as specific markers for different cell types and their functions in vertebrates. This characteristic makes antibodies an important reagent for use in biomedical research to diagnose diseases, and for treatment of infectious diseases and cancer.
Chimeric antigen receptor T cells (also known as CAR-T cells) are T cells that have been genetically engineered to produce an artificial T-cell receptor for applications in immunotherapy. The application of chimeric antigen receptor (CAR) T cells is among the most promising advances in cancer immunotherapy research while being the first of its kind to receive US FDA approval.
BioCytoceuticals leads the industry in cellular therapy with commitment to provide the most appropriate solutions to address the needs of our clients. Our expert team of scientists applies comprehensive methods and most detail-oriented scrutiny to ensure only top-tier outcome is submitted.
If you have any special enquiries regarding our services, please do not hesitate to contact us. Our highly professional technical supporting staffs will make sure your requests are faithfully received. We are looking forward to earning your business.
Inquiry
